Circulating tumour DNA (ctDNA) to guide adjuvant chemotherapy and surveillance strategies in patients with stage II colon cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1085531

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This study is attempting to demonstrate that an adjuvant therapy strategy based on ctDNA results will reduce the number of patients with stage II colon cancer receiving adjuvant chemotherapy without compromising recurrence free survival. Prospective multi-centre study enrolling 450 stage II colon cancer patients. Patients will be randomized 2:1 to be treated according to ctDNA results (Arm A, n = 300), or per standard clinical criteria (Arm B, n = 150).

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $1,227,186.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology and Carcinogenesis not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomarkers | cancer follow-up | cancer prognosis | colorectal cancer | risk assessment

Related Links